BaFin probes Eckert & Ziegler’s 2024 accounts over Pentixapharm spin-off treatment

Reuters2026/07/22 05:27

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BaFin opened a special review of Eckert & Ziegler’s 2024 consolidated financial statements tied to the October 2024 Pentixapharm spin-off.
Regulator is assessing whether ongoing control relationships blocked off-balance-sheet derecognition of Pentixapharm assets and liabilities.
A different accounting treatment could shift the items into earnings, lifting profit from discontinued operations in 2024.
Company flagged no impact on operating key figures or subsequent years from the potential reclassification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2369628_en) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BaFin probes Eckert & Ziegler’s 2024 accounts over Pentixapharm spin-off treatment

You may also like

Crypto prices